Refractory vasodilation and catecholamine resistance are common in septic shock. Changes in receptor signaling, excessive production of nitric oxide, and absolute or relative deficiencies of vasoactive hormones, including cortisol, vasopressin, and angiotensin II, play a role. Angiotensin II (Ang II) was previously available as a vasopressor but removed from the market in the 1990s. Interest was re-ignited following the Angiotensin II for the Treatment of Vasodilatory Shock (ATHOS-3) study, a randomized controlled trial in patients with refractory shock which confirmed that Ang II was effective at maintaining mean arterial pressure and reducing norepinephrine requirements without an increase in side effects \[[@CR1]\]. Patients receiving renal replacement therapy also had improved survival and faster recovery of renal function \[[@CR2]\]. Recent literature noted the potential role of Ang II in other types of shock \[[@CR3]\].

The major physiological effects of Ang II relate to maintenance of hemodynamic stability and fluid and electrolyte regulation (Table [1](#Tab1){ref-type="table"}). Angiotensinogen, the precursor of angiotensin, is produced primarily by the liver and released into the systemic circulation where it is converted to angiotensin I (Ang I). Ang I is cleaved into Ang II, predominantly by angiotensin converting enzyme (ACE), an endothelium bound protein that is primarily expressed in the pulmonary and renal capillary beds. In patients with acute respiratory distress syndrome, ACE insufficiency has been reported \[[@CR4]\]. In veno-arterial ECMO, a proportion of blood bypasses the lungs, which further limits the conversion of Ang I to Ang II. Other conditions associated with reduced Ang II levels include Gram-negative sepsis where endotoxinemia can deactivate ACE. Importantly, low levels of Ang II and ACE are associated with increased mortality \[[@CR5]\].Table 1Main physiological effects of angiotensin IIOrgan systemPhysiological effectsVascular● Vasoconstriction of venous and arterial vessels\
● Increased vascular permeabilityRenal● Stimulation of Na reabsorption and H^+^ excretion in the proximal tubule via Na^+^/H^+^ exchanger\
● Stimulation of the release of aldosterone\
● Variable effects on glomerular filtration and renal blood flow depending on the physiological and pharmacological setting:\
➢ constriction of the afferent and efferent glomerular arterioles with greater effect on the efferent vessel\
➢ constriction of the glomerular mesangium\
➢ enhanced sensitivity to tubulo-glomerular feedback\
➢ increased local release of prostaglandins which antagonize renal vasoconstrictionEndocrine● Stimulation of the secretion of vasopressin from the posterior pituitary gland\
● Secretion of ACTH\
● Enhanced release of noradrenaline from postganglionic sympathetic fibersNervous● Enhancement of noradrenaline secretionCardiac● Mediation of cardiac remodeling through activated tissue RAS in cardiac myocytesCoagulation● Prothrombotic potentialImmune● Promotion of cell growth and inflammation\
● Increased expression of endothelium-derived adhesion molecules\
● Synthesis of pro-inflammatory cytokines and chemokines\
● Generation of reactive oxygen species*Abbreviations*: *ACTH* adrenocorticotropin hormone, *Ang II* angiotensin II, *GFR* glomerular filtration rate, *RAS* renin-angiotensin system

We report the successful management of seven patients (four male; mean age 36 years) with severe cardiorespiratory failure and refractory shock treated with extracorporeal membrane oxygenation (ECMO) who received Ang II in the context of the ATHOS-3 trial \[[@CR1]\] or a compassionate use program (Table [2](#Tab2){ref-type="table"}). Following initiation of Ang II, a profound effect on blood pressure was seen and the doses of vasopressors were reduced quickly. Time to cessation of vasopressors and catecholamines ranged from 16 h to 8 days. Six patients were discharged home alive.Table 2Patient characteristicsPatient 1Patient 2Patient 3Patient 4Patient 5Patient 6Patient 7Age (years)23264148385037GenderMMFFMFMPrimary acute illnessInfluenza A infectionSepsisInfluenza B and MRSA pneumoniaSepsis post acute MIAspiration pneumoniaPulmonary embolismType A aortic dissectionSecondary acute illnessCardiac arrest due to pericardial effusionCardiac arrestSepsis and cardiogenic shockDrug overdose (calcium channel blocker and beta blocker)Multi-organ failurePoly-microbial sepsisConfounding factorsNoneIdiopathic dysautonomy and mast cell activation syndromeObesityHIV positiveObesityRecent craniotomy for meningiomaLarge RV and LV infarctType of ECMOVA ECMOVA ECMOVA ECMOVV ECMOVV ECMOVA ECMOVA ECMOVasopressor support \*pre-Ang II administrationNorepinephrine 0.4\
Vasopressin 4\
Epinephrine 0.07Norepinephrine 1\
Vasopressin 6\
Epinephrine 0.3Epinephrine 0.18\
Vasopressin 2Norepinephrine 0.59Norepinephrine 1.36\
Vasopressin 2.4Norepinephrine 0.2\
Vasopressin 5\
Milrinone 0.25\
Epinephrine 0.05Norepinephrine 0.1\
Vasopressin 4\
Epinephrine 0.02MAP at initiation of Ang II \[mmHg\]Missing577670635959Dose of Ang II \[ng/kg/min\]MissingMissing2020402020Duration of Ang II7 days46 h50 h27.5 h80 hTime to cessation of all vasopressors after initiation of Ang IIMissing48 hMissing16 h6 days8 daysNAAdverse events during Ang II infusionNoneNoneReversible digital ischemiaNoneNoneNoneBowel ischemiaPatient outcomeSurvivalSurvivalSurvivalSurvivalSurvivalSurvivalDeceasedDuration on ECMO \[days\]17511949914Length of stay in ICU \[days\]1763012821221314Abbreviations: *Ang II* angiotensin II, *ECMO* extracorporeal membrane oxygenation, *ICU* intensive care unit, *LV* left ventricle, *MAP* mean arterial pressure, *MRSA* methicillin-resistant *staphylococcus aureus*, *RV* right ventricle, *VA* veno-arterial, *VV* veno-venous\*Units of drugs: norepinephrine in μg/kg/min; epinephrine in μg/kg/min; vasopressin in units/h; milrinone in μg/kg/min

In conclusion, in patients with severe cardio-respiratory failure requiring ECMO, treatment with Ang II in addition to standard supportive care enabled rapid decatecholaminization. Underlying ACE deficiency may be a contributing factor. Further studies are necessary to confirm the findings.
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